CR20230415A - Compuesto de heteroarilcarboxamida - Google Patents
Compuesto de heteroarilcarboxamidaInfo
- Publication number
- CR20230415A CR20230415A CR20230415A CR20230415A CR20230415A CR 20230415 A CR20230415 A CR 20230415A CR 20230415 A CR20230415 A CR 20230415A CR 20230415 A CR20230415 A CR 20230415A CR 20230415 A CR20230415 A CR 20230415A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibody
- cancer
- carboxamide compound
- immunocyte
- activation
- Prior art date
Links
- -1 Heteroaryl carboxamide compound Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 6
- 230000004913 activation Effects 0.000 abstract 3
- 238000009175 antibody therapy Methods 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000012790 confirmation Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporciona un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o el cáncer resistente a la terapia con anticuerpo anti-PD-1/anticuerpo anti-PD-L1. Los presentes inventores han realizado estudios sobre un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o cáncer resistente a la terapia con anticuerpo anti-PD-1/anticuerpo anti-PD-L1, y han confirmado que un compuesto de heteroarilcarboxamida tiene un efecto inhibidor x de DGK (DGKzeta), lo que conduce a la finalización de la presente invención. El compuesto de heteroarilcarboxamida de la presente invención tiene un efecto inhibidor x de DGK y puede usarse como un agente terapéutico para el tratamiento de cáncer relacionado con la activación de células inmunitarias o cáncer resistente a la terapia con anticuerpo anti-PD-1/anticuerpo anti-PD-L1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020197899 | 2020-11-30 | ||
PCT/JP2021/043540 WO2022114164A1 (ja) | 2020-11-30 | 2021-11-29 | ヘテロアリールカルボキシアミド化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230415A true CR20230415A (es) | 2023-09-08 |
Family
ID=81754515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230415A CR20230415A (es) | 2020-11-30 | 2021-11-29 | Compuesto de heteroarilcarboxamida |
Country Status (18)
Country | Link |
---|---|
US (2) | US20240043403A1 (es) |
EP (1) | EP4253373A1 (es) |
JP (1) | JP7397452B2 (es) |
KR (1) | KR20230116838A (es) |
CN (1) | CN116528864A (es) |
AR (1) | AR124172A1 (es) |
AU (1) | AU2021389180A1 (es) |
CA (1) | CA3203285A1 (es) |
CL (1) | CL2023001534A1 (es) |
CO (1) | CO2023008271A2 (es) |
CR (1) | CR20230415A (es) |
DO (1) | DOP2023000107A (es) |
EC (1) | ECSP23048974A (es) |
IL (1) | IL303209A (es) |
MX (1) | MX2023006318A (es) |
PE (1) | PE20231986A1 (es) |
TW (1) | TW202229256A (es) |
WO (1) | WO2022114164A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
WO2023248109A1 (en) | 2022-06-20 | 2023-12-28 | Astellas Pharma Inc. | Methods for treating patients with locally advanced and/or metastatic solid tumors using a dgk zeta inhibitor |
WO2024108100A1 (en) * | 2022-11-18 | 2024-05-23 | Incyte Corporation | Heteroaryl fluoroalkenes as dgk inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7381401B2 (en) | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
BRPI0607308A2 (pt) | 2005-01-25 | 2009-08-25 | Synta Pharmaceuticals Corp | compostos, composições farmacêuticas e usos dos referidos compostos |
US8455658B2 (en) | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
JP5182088B2 (ja) | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
AU2007314342B2 (en) | 2006-10-31 | 2013-02-21 | Merck Sharp & Dohme Corp. | Anilinopiperazine Derivatives and methods of use thereof |
US20200385371A1 (en) | 2017-09-06 | 2020-12-10 | Propellon Therapeutics Inc. | Inhibitors of wdr5 protein-protein binding |
KR20210024586A (ko) * | 2018-06-27 | 2021-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
AR120896A1 (es) | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
-
2021
- 2021-11-29 IL IL303209A patent/IL303209A/en unknown
- 2021-11-29 CA CA3203285A patent/CA3203285A1/en active Pending
- 2021-11-29 CR CR20230415A patent/CR20230415A/es unknown
- 2021-11-29 PE PE2023001705A patent/PE20231986A1/es unknown
- 2021-11-29 CN CN202180080083.8A patent/CN116528864A/zh active Pending
- 2021-11-29 TW TW110144382A patent/TW202229256A/zh unknown
- 2021-11-29 MX MX2023006318A patent/MX2023006318A/es unknown
- 2021-11-29 AU AU2021389180A patent/AU2021389180A1/en active Pending
- 2021-11-29 WO PCT/JP2021/043540 patent/WO2022114164A1/ja active Application Filing
- 2021-11-29 EP EP21898136.3A patent/EP4253373A1/en active Pending
- 2021-11-29 JP JP2022565480A patent/JP7397452B2/ja active Active
- 2021-11-29 US US18/254,829 patent/US20240043403A1/en active Pending
- 2021-11-29 AR ARP210103290A patent/AR124172A1/es unknown
- 2021-11-29 KR KR1020237021502A patent/KR20230116838A/ko unknown
-
2023
- 2023-05-29 CL CL2023001534A patent/CL2023001534A1/es unknown
- 2023-05-29 DO DO2023000107A patent/DOP2023000107A/es unknown
- 2023-06-23 CO CONC2023/0008271A patent/CO2023008271A2/es unknown
- 2023-06-29 EC ECSENADI202348974A patent/ECSP23048974A/es unknown
- 2023-11-28 US US18/521,400 patent/US20240101532A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL303209A (en) | 2023-07-01 |
US20240043403A1 (en) | 2024-02-08 |
JPWO2022114164A1 (es) | 2022-06-02 |
AR124172A1 (es) | 2023-02-22 |
DOP2023000107A (es) | 2023-07-16 |
WO2022114164A1 (ja) | 2022-06-02 |
ECSP23048974A (es) | 2023-07-31 |
CA3203285A1 (en) | 2022-06-02 |
PE20231986A1 (es) | 2023-12-12 |
EP4253373A1 (en) | 2023-10-04 |
CO2023008271A2 (es) | 2023-07-21 |
CL2023001534A1 (es) | 2023-11-10 |
JP7397452B2 (ja) | 2023-12-13 |
CN116528864A (zh) | 2023-08-01 |
US20240101532A1 (en) | 2024-03-28 |
MX2023006318A (es) | 2023-06-14 |
AU2021389180A1 (en) | 2023-06-29 |
KR20230116838A (ko) | 2023-08-04 |
TW202229256A (zh) | 2022-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20230415A (es) | Compuesto de heteroarilcarboxamida | |
CR20220328A (es) | Compuesto de piridazinil-tiazolcarboxamida | |
JOP20190186A1 (ar) | مركب كينازولين | |
MX2023009521A (es) | Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d. | |
MX2020008777A (es) | Inmunoterapias relacionadas con el microbioma. | |
PH12017502270A1 (en) | Combination therapy for the treatment of cancer | |
PH12020550491A1 (en) | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | |
SG11201908234WA (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
PH12016501527A1 (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
PH12017500436A1 (en) | Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence | |
MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
MX2022006280A (es) | Uso de la composición para potenciar el efecto anticancerígeno que contiene el inhibidor de err? como principio activo. | |
MX2023009520A (es) | Compuesto de 4-aminoquinazolina. | |
MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
MX2020008275A (es) | Metodos para tratar trastornos mitocondriales. | |
MX2023002482A (es) | Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
WO2023240082A3 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
EA201991302A1 (ru) | Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1 и лекарственными средствами, ингибиторами контрольных точек иммунного ответа | |
IL288242A (en) | Nitrogen heteroaryl compounds, preparations containing alt compounds and their use for cancer treatment | |
MX2022005991A (es) | Farmaco combinado. | |
EP4005572A4 (en) | BENZAMIDE DERIVATIVE, METHOD FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS AN ACTIVE SUBSTANCE FOR THE PREVENTION OR TREATMENT OF CANCER | |
MX2019001210A (es) | Composicion farmaceutica anticancer. | |
WO2018236185A3 (ko) | 패혈증 치료제 및 이의 스크리닝 방법 |